You are here: Industry Insights > Herceptin

News List

FDA Approves Kanjinti (trastuzumab-anns), a Biosimilar to Herceptin drugs
June 17, 2019
FDA Approves Kanjinti.
Herceptin has been Excellent over the Two Decades PharmaSources/Miling
April 10, 2019
The subcutaneous injection: Herceptin Hylecta of the star drug Herceptin under Roche has recently been approved by FDA for...
Celltrion/Teva’s Herceptin biosimilar approved in US pharmaphorum
December 18, 2018
The FDA has approved Celltrion and Teva’s biosimilar of Roche’s breast cancer drug Herceptin, the second potential competitor to the cancer blockbuster in the US.
FDA Approves Herzuma (trastuzumab-pkrb), a Biosimilar to Herceptin drugs
December 17, 2018
Celltrion, Inc. and Teva Pharmaceutical Industries Ltd. today announced that the U.S. Food and Drug Administration (FDA) has approved Herzuma (trastuzumab-pkrb).....
Phase III KATHERINE trial crossed early reporting boundary and met its primary endpoint europeanpharmaceuticalreview
December 06, 2018
A phase III clinical trial showed that neoadjuvant chemotherapy and trastuzumab reduced the risk of recurrence of HER2-positive early-stage breast cancer…
Roche aims for Kadcyla expansion with new early breast cancer data fiercepharma
December 06, 2018
Roche is hoping to grow sales for new drugs as biosim competition begins to erode its top blockbusters, and now the drugmaker has unveiled new data that just might give its breast cancer drug Kadcyla a boost.
Napp secures distribution rights to Celltrion’s Herzuma pharmatimes
July 23, 2018
Napp Pharmaceuticals has secured itself exclusive UK distribution rights to Celltrion Healthcare’s Herceptin biosimilar Herzuma.
Roche scrambles to boost Herceptin supply in China after insurance OK triggers shortage fiercepharma
June 06, 2018
When Roche got Herceptin onto China’s national insurance program, it didn’t expect demand to surge so quickly, overwhelming its production capacity there.
Herceptin biosimilar Herzuma launched in Europe pharmatimes
May 07, 2018
Mundipharma said its network of companies has kicked off the rollout of Celltrion’s Herceptin biosimilar Herzuma in Europe.
Caris Life Sciences Announces Published Results Showing that its ADAPT Biotargeting System Effectively Stratified Breast Cancer Patients Based on Their Benefit from Trastuzumab Treatment (Herceptin) biospace
March 26, 2018
Caris Life Sciences®today announced publication of an article

Previous page 1 2 3 Next page